Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CBL0137 (Curaxin 137), a metabolically stable curaxin, activates p53 (EC50: 0.37 μM) and inhibits NF-κB (EC50: 0.47 μM). It functionally inactivates the facilitates chromatin transcription complex (FACT), driving the effects on p53 and NF-κB and promoting cancer cell death. CBL0137 has broad anticancer activity in mice when administered orally, eradicates drug-resistant cancer stem cells, and potentiates the efficacy of gemcitabine in preClinicalal models of pancreatic cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 83.00 | |
5 mg | In stock | $ 377.00 | |
10 mg | In stock | $ 553.00 | |
25 mg | In stock | $ 867.00 | |
50 mg | In stock | $ 1,190.00 | |
100 mg | In stock | $ 1,590.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 377.00 |
Description | CBL0137 (Curaxin 137), a metabolically stable curaxin, activates p53 (EC50: 0.37 μM) and inhibits NF-κB (EC50: 0.47 μM). It functionally inactivates the facilitates chromatin transcription complex (FACT), driving the effects on p53 and NF-κB and promoting cancer cell death. CBL0137 has broad anticancer activity in mice when administered orally, eradicates drug-resistant cancer stem cells, and potentiates the efficacy of gemcitabine in preClinicalal models of pancreatic cancer. |
Targets&IC50 | NF-κB:0.47 μM (EC50), p53:0.37 μM (EC50) |
Synonyms | Curaxin 137, CBLC137 |
Molecular Weight | 336.43 |
Formula | C21H24N2O2 |
CAS No. | 1197996-80-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (74.31 mM), Sonication is recommended.
H2O: Insoluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CBL0137 1197996-80-7 Apoptosis NF-Κb p53 NF-κB Curaxin 137 CBL 0137 CBLC 137 CBLC-137 CBL-0137 CBLC137 inhibitor inhibit